Gene:
HCN4
hyperpolarization activated cyclic nucleotide-gated potassium channel 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA394

Details

Cytogenetic Location: chr15 : q24.1 - q24.1
GP mRNA Boundary: chr15 : 73612200 - 73661605
GP Gene Boundary: chr15 : 73609200 - 73671605
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

Publications related to HCN4: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two pacemaker channels from human heart with profoundly different activation kinetics. The EMBO journal. 1999. Ludwig A, et al. PubMed

LinkOuts

Entrez Gene:
10021
OMIM:
163800
605206
613123
UCSC Genome Browser:
NM_005477
RefSeq RNA:
NM_005477
RefSeq Protein:
NP_005468
RefSeq DNA:
AC_000058
AC_000147
NC_000015
NG_009063
NT_010194
NW_001838218
NW_925884
UniProtKB:
HCN4_HUMAN (Q9Y3Q4)
Ensembl:
ENSG00000138622
GenAtlas:
HCN4
GeneCard:
HCN4
MutDB:
HCN4
ALFRED:
LO065355Y
HuGE:
HCN4
Comparative Toxicogenomics Database:
10021
ModBase:
Q9Y3Q4
HumanCyc Gene:
HS06520
IUPHAR Receptor:
HCN4 (403)
HGNC:
16882

Common Searches